OrbiMed’s Baxter International BAX Stock Holding History

OrbiMed’s Portfolio BAX Stock Details BAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-300,000	Closed	-$13.7M	–	129
2023 Q2	$13.7M	Sell	300,000 -50,000	-14%	-$2.18M	0.25%	78
2023 Q1	$14.2M	Buy	+350,000	New	+$14.8M	0.28%	77

Other funds holding BAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

OrbiMed's BAX Position: Q4 2023 in Review

OrbiMed sold out of Baxter International (BAX) in Q4 2023, closing a stake of 2,239,900 shares — an estimated $84.5M sold.

OrbiMed first reported a position in BAX in Q2 2013 and held it in 8 quarters. The position peaked at $154M in Q2 2023. 913 funds tracked by Wall St. Rank hold BAX as of Q4 2023.

OrbiMed reported no remaining Baxter International position as of Q4 2023 after selling out during the quarter.
OrbiMed sold 2,239,900 Baxter International shares in Q4 2023, an estimated $84.5M.
OrbiMed first reported a position in Baxter International in Q2 2013 and held it in 8 quarters.
OrbiMed's Baxter International position peaked at $154M in Q2 2023.
913 funds tracked by Wall St. Rank held Baxter International as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.